The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.

Feist E, Luggen ME, Nasonov EL, Yakushin SS, Bukhanova DV, Egorova AN, Grishin SA, Samsonov MY, Smolen JS.

Open source

DOI: 10.1186/s13075-025-03682-w
Published: 2025-11-14
Container: Arthritis Res Ther
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13075-025-03682-w,
  title = {The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.},
  author = {Feist E and  Luggen ME and  Nasonov EL and  Yakushin SS and  Bukhanova DV and  Egorova AN and  Grishin SA and  Samsonov MY and  Smolen JS.},
  year = {2025},
  journal = {Arthritis Res Ther},
  doi = {10.1186/s13075-025-03682-w},
  url = {https://doi.org/10.1186/s13075-025-03682-w}
}

RIS

TY  - JOUR
TI  - The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.
AU  - Feist E
AU  -  Luggen ME
AU  -  Nasonov EL
AU  -  Yakushin SS
AU  -  Bukhanova DV
AU  -  Egorova AN
AU  -  Grishin SA
AU  -  Samsonov MY
AU  -  Smolen JS.
PY  - 2025
JO  - Arthritis Res Ther
DO  - 10.1186/s13075-025-03682-w
UR  - https://doi.org/10.1186/s13075-025-03682-w
ER  -

APA

E, F., ME, L., EL, N., SS, Y., DV, B., AN, E., SA, G., MY, S., & JS., S. (2025). The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.. Arthritis Res Ther. https://doi.org/10.1186/s13075-025-03682-w

Source records

europe-pmc · retrieved 2026-09-26T21:50:33.821Z
doaj · retrieved 2026-09-26T21:50:33.815Z